SAB Biotherapeutics Income Statement (2020-2026) | SABS

Income Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
1.48M2.73M4.35M4.36M4.36M5.09M5.09M5.29M5.29M5.52M9.28M9.28M9.28M9.34M9.35M9.35M10.66M47.66M53.56M90.99M
Revenue & cost
Revenue (Quarter)
14.68M11.06M11.80M6.35M3.59M2.16M0.58M0.09M1.27M0.31M0.94M0.26M0.11M
Operating items
Research & Development (Quarter)
15.07M10.65M13.32M8.58M7.35M7.14M4.54M3.66M4.02M4.30M8.15M6.82M7.83M7.65M7.66M7.00M8.97M10.73M13.40M16.17M
Selling, General & Administrative (Quarter)
3.60M7.75M5.19M4.31M4.04M2.88M3.45M2.90M2.57M14.88M4.19M3.64M3.48M2.47M3.11M2.74M3.71M5.04M6.60M7.21M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
18.67M18.40M18.51M12.89M11.40M10.02M7.98M6.56M6.59M19.18M12.34M10.46M11.31M10.12M10.77M9.73M12.68M15.77M20.00M23.38M
Operating Income (Quarter)
-3.99M-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M-23.38M
EBIT (Quarter)
-3.99M-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M-23.38M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.01M0.01M0.02M0.02M0.03M0.06M0.03M0.01M0.48M0.50M0.37M0.28M0.14M0.06M0.01M0.66M0.70M1.05M1.71M
Other Non Operating Income (Quarter)
0.00M0.00M7.79M1.67M0.00M0.03M0.10M0.34M0.48M0.37M0.75M0.85M0.55M0.30M0.77M1.53M0.63M0.35M
Non Operating Income (Quarter)
-0.07M-4.21M7.79M1.67M0.73M0.01M0.05M-0.40M0.22M-3.98M6.36M2.87M0.96M-1.39M5.58M-0.38M58.12M-1.09M1.13M0.89M
Net income details
EBT (Quarter)
-4.06M-11.55M1.08M-4.87M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.57M-10.97M-10.45M-12.75M-15.13M-46.51M-50.77M
Tax Provisions (Quarter)
0.09M-0.09M
Profit After Tax (Quarter)
-4.06M-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M45.45M-16.86M-18.87M-22.49M
Income from Non-Controlling Interests (Quarter)
0.08M-0.23M0.07M0.07M0.07M-0.21M0.07M0.07M0.07M-0.21M0.07M0.07M
Income from Continuing Operations (Quarter)
-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.57M-10.97M-10.45M-12.75M-15.13M-46.51M-50.77M
Consolidated Net Income (Quarter)
-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.57M-10.97M-10.45M-12.75M-15.13M-46.51M-50.77M
Income towards Parent Company (Quarter)
-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.57M-10.97M-10.45M-12.75M-15.13M-46.51M-50.77M
Net Income towards Common Stockholders (Quarter)
-4.06M-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M-12.75M-15.13M-18.87M-22.49M
Additional items
EPS (Basic) (Quarter)
-2.75-4.230.23-1.11-1.64-1.81-1.46-1.36-0.97-4.14-0.54-0.79-1.12-1.23-0.56-1.09-1.20-0.34-0.35-0.28
EPS (Diluted) (Quarter)
-1.56-4.230.22-1.11-1.64-1.81-1.46-1.36-0.97-4.14-0.54-0.79-1.12-1.23-0.56-1.09-0.16-0.25-0.35-0.28
Shares Outstanding (Quarter)
1.48M2.73M4.31M4.30M4.30M4.35M5.04M5.04M5.24M5.52M9.24M9.26M9.26M9.26M9.29M9.29M10.66M44.79M53.56M79.75M
Shares Outstanding (Diluted) (Quarter)
2.60M2.73M4.58M4.30M4.30M4.35M5.04M5.04M5.24M5.52M9.24M9.26M9.26M9.26M9.29M9.29M77.86M61.34M53.56M79.75M
EBITDA (Quarter)
-3.99M-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M-23.38M
Interest Expenses (Quarter)
0.28M0.07M0.31M2.15M0.35M-0.64M0.12M1.66M0.44M0.08M0.24M0.25M0.26M-0.30M0.26M0.73M0.73M0.06M27.56M29.10M
Tax Rate (Quarter)
8.561.90